Trending Topic

3D rendered Medical Illustration of Male Anatomy - Rectal Cancer.
14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Gabriel Valagni, Nkafu Bechem Ndemazie, Tiago Biachi de Castria

Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 It was first identified by Callahan et al. in 1996 as an active impurity in the herbicide trifluralin, which […]

Maternal Epithelial Ovarian Cancer

Julia Palmer, John Tidy, Manu Vatish
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Jun 3rd 2011 European Oncology, 2009;5(1):64-6 DOI: https://doi.org/10.17925/EOH.2009.05.1.64
Select a Section…
1

Abstract

Overview

Maternal epithelial ovarian cancer is rare; its rarity is reflected by the paucity of reported cases in the literature. Its incidence appears to be increased in the older pregnant patient, and since childbearing among older patients has markedly risen in more recent years it is likely that this disease will become more common. Currently, there are no definitive guidelines regarding patient management in maternal epithelial ovarian cancer. Management should therefore be case-dependent, individualised and multidisciplinary in nature. Data centralisation for individual cases including detailed information on clinico-pathological variables, treatment regimens, maternal and neonatal outcomes may be beneficial in identifying optimal management strategies in these rare tumours.

2

Article

The Clinical Problem
Malignant epithelial ovarian cancer diagnosed during pregnancy is rare, with an estimated incidence of 1:12,000 to 1:50,000 pregnancies.1–3 A recent review4 identified 28 publications pertaining to maternal malignant epithelial ovarian cancer, spanning a time period of 49 years. The paucity of published data and low incidence of maternal epithelial ovarian cancer is likely to reflect the low prevalence of ovarian cancer in younger women. The incidence of maternal primary epithelial ovarian cancer appears to be increased in the older pregnant patient.4 In the UK there has been a two-fold increase in the birth rate in women >30 years of age and a three-fold increase in women >40 years of age since 1975.5 Similarly, in the US since 1980 the proportion of first births has increased three-fold in women ≥30 years of age, sixfold in women ≥35 years of age and 15-fold in women ≥40 years of age since 1980.6 Overall it is uncertain whether ovarian cancer associated with pregnancy is increasing,7 although this seems possible as childbearing among older patients increases.

Diagnosis
Patients may present with pain, abdominal distension or a mass, although many are asymptomatic at the time of detection.4 Approximately 50% of maternal epithelial ovarian cancers are detected as an incidental mass on routine pelvic or ultrasound examinations, with the majority detected in the first and second trimester. Detection at the time of Caesarean section or in the postnatal period is less common.4

To read full article please click here

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup